COMMUNIQUÉS West-GlobeNewswire

Life Biosciences Presents New Data at ARDD 2025 on the Company’s Partial Epigenetic Reprogramming Platform in Liver and Ocular Diseases
26/08/2025
ER-300 improves key biomarkers of liver health in an animal model of MASH These data, along with additional ER-100 preclinical data from a nonhuman primate model of NAION demonstrating clear restoration of methylation [...]
Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis
26/08/2025
VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered [...]
CancerVax Achieves Major Milestones and Files Foundational Patent Application
26/08/2025
The Company filed a substantial non-provisional PCT patent application seeking worldwide protection for its novel cancer treatment platform Lehi, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, August 26, 2025 – CancerVax [...]
PathAI Expands AISight® Dx Primary Diagnosis Clearance to Support VENTANA DP 200 and DP 600 Slide Scanners Through Predetermined Change Control Plan (PCCP)
26/08/2025
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced the expansion of the AISight® Dx digital pathology image management [...]
PannTheraPi prepares plans to conduct its first Phase IIa clinical trial with PTI5803 in patients with resistant epilepsy and accelerate the development of its proprietary pipeline
26/08/2025
PannTheraPi prepares plans to conduct its first Phase IIa clinical trial with PTI5803 in patients with resistant epilepsy and accelerate the development of its proprietary pipeline Pre-submission file completed with [...]
PannTheraPi se prépare pour mener son premier essai clinique de phase IIa avec le PTI5803 chez des patients atteints d'épilepsie résistante et accélérer le développement de son portefeuille propriétaire
26/08/2025
PannTheraPi se prépare pour mener son premier essai clinique de phase IIa avec le PTI5803 chez des patients atteints d'épilepsie résistante et accélérer le développement de son portefeuille propriétaire Dossier de pré- [...]
Publication of statement by the Board of Directors in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira
26/08/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, [...]
Publication of offer document in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira and lowering of minimum acceptance condition to 75%
26/08/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, [...]
Ariceum Therapeutics Appoints David Schilansky as Chief Executive Officer and Announces New Leadership to Advance Next Phase of Development
26/08/2025
David Schilansky transitions to CEO, bringing 25 years of company-building, scaling and financing to advance Ariceum’s pipeline of novel radiotherapeutics Initiation of Phase 1/2 SANTANA-225 study of 225Ac-SSO110 in [...]
Nicox Announces Shareholder Q&A Webpage Available
26/08/2025
Press Release Nicox Announces Shareholder Q&A Webpage Available August 26, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology [...]
Nicox annonce la mise en ligne d’une page « Questions-Réponses » sur son site internet
26/08/2025
Communiqué de presse Nicox annonce la mise en ligne d’une page « Questions-Réponses » sur son site internet 26 août 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, [...]
Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
26/08/2025
ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio [...]
Synergy CHC Corp. Announces Pricing of $4.375 Million Public Offering
26/08/2025
WESTBROOK, Maine, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (Nasdaq: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced the pricing of an underwritten public [...]
Hydreight Achieves 33% YoY H1 Revenue Growth, Records 3rd Consecutive Quarter of Profitability, and Strengthens Performance Across Verticals
26/08/2025
“We had a great first 6 months, with 33% year-over-year growth. We have also exceeded our internal metrics across all verticals in the first seven months of the year, reinforcing the strength of our strategy. A key [...]
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
25/08/2025
PRINCETON, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the [...]
Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway
25/08/2025
- U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026 - Patient dosing expected to begin in Australia in Q4 2025 HUNTSVILLE, AL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, [...]
Memgen Announces First Patient Dosed in Phase 1 Combination Cohort of MEM-288 Plus Docetaxel in Advanced Non–Small Cell Lung Cancer
25/08/2025
Study designed to assess safety and antitumor activity; data intended to inform a planned randomized Phase 2 study TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Memgen, Inc., a clinical-stage biotechnology company [...]
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025
25/08/2025
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients [...]
Option Care Health To Participate in Upcoming Investor Conferences
25/08/2025
BANNOCKBURN, Ill., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will [...]

Pages